Abstract
Bluestem Biosciences, a synthetic biology start-up, has raised $5 million in seed financing to pursue the production of chemicals via anaerobic fermentation. The company told the trade group Bio Nebraska it plans to license yeast strains and fermentation processes to companies that own fermentation infrastructure. Bluestem will use computational tools to develop a product pipeline. The company’s team includes alumni from synthetic biology companies such as Ginkgo Bioworks, Zymergen, and Amyris.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
